Most Read Articles
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roshini Claire Anthony, 4 days ago

A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.

Roshini Claire Anthony, 2 days ago

The use of intramuscular depot medroxyprogesterone acetate (DMPA-IM) did not increase a woman’s risk of acquiring HIV compared with the use of a copper intrauterine device (IUD) or a levonorgestrel implant, results of a study conducted by the ECHO* Trial Consortium show.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).

Water-free cyclosporine formulation safe, effective for dry eye disease

17 Jun 2019

Treatment with water-free cyclosporine formulation (CyclASol) at either 0.1% or 0.05% concentration is tolerable and provides effective relief of the signs of dry eye disease (DED), according to data from a phase II study.

The study randomly assigned 207 DED patients (mean age, 62.4 years; 73.9 percent female) to one of the following treatment arms: CyclASol 0.05% (n=51), CyclASol 0.1% (n=51), vehicle (n=52) and cyclosporine emulsion (n=53). Dosed twice daily, the 16-week treatment was initiated after a 2-week run-in period.

Efficacy endpoints included total and subregion corneal fluorescein staining, conjunctival staining, visual analogue scale (VAS) for dry eye symptoms, VAS severity, and Ocular Surface Disease Index (OSDI) questionnaire scores.

During the 16-week treatment period, CyclASol consistently reduced corneal and conjunctival staining compared with both the vehicle and emulsion. The onset of effect occurred early at day 14.

In mixed-effects model–based approach, the effect of CyclASol was statistically significant compared with that of the vehicle (total corneal staining, p<0.1; central corneal staining, p<0.001; conjunctival staining, p<0.01). CyclASol also demonstrated a significant effect on OSDI as symptom parameter (p<0.01).

Dryness symptoms, as measured by VAS, improved across all treatment arms, with no significant difference between CyclASol and vehicle.

In terms of safety, the rate of ocular adverse events was low in all treatment arms. Treatment-emergent adverse events were reported in 65 patients (31.4 percent) overall, all of which were mild-to-moderate in severity.

The present data show that the new water-free cyclosporine formulation relieves the signs of DED as early as after 2 weeks of treatment, with excellent safety, tolerability and comfort profile, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roshini Claire Anthony, 4 days ago

A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.

Roshini Claire Anthony, 2 days ago

The use of intramuscular depot medroxyprogesterone acetate (DMPA-IM) did not increase a woman’s risk of acquiring HIV compared with the use of a copper intrauterine device (IUD) or a levonorgestrel implant, results of a study conducted by the ECHO* Trial Consortium show.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).